ანოტაცია
ღვიძლის პირველადი კიბოს დროს პაციენტების კვლევაში კომპიუტერული ტომოგრაფიის ჩართვით შესაძლებელია მკაფიოდ განვასხვავოთ ერთმანეთისგან ჰეპატოცელულური და ქოლანგიოცელულური კიბო. ჰეპატოცელულური კიბოსთვის დამახასიათებელია ღვიძლის ერთ-ერთი წილის დაზიანება, რომელიც შეიძლება მთლიანად დაიკავოს პათოლოგიურმა წარმონაქმნმა და, რაც მთავარია, არ აღინიშნება სანაღვლე გზების დილატაცია. ჰოლანგიოცელულური კიბოს დროს ძირითადად ზიანდება ღვიძლის ცენტრალური ნაწილები, კარის მიმდებარედ, ღვიძლშიდა სადინრების გაფართოებით, ხოლო პერიფერიული ნაწილები რჩება ინტაქტური.
წყაროები
Abreu RM, Ferreira CS, Nasser PD, et al. Hepatocellular Carcinoma:The final moments of life. J Cancer Ther. 2013;4:377–83. [Google Scholar]
Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR) J Hepatol.2012;57:675–88. [PubMed] [Google Scholar]
Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol. 2014;6:626–31. [PMC free article] [PubMed] [Google Scholar]
Alqurashi N, Hashimi SM, Wei MQ. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway:potential for novel anticancer therapeutics. Int J Mol Sci. 2013;14:3874–900. [PMC free article] [PubMed] [Google Scholar]
Anwar SL, Lehmann U. MicroRNAs:Emerging novel clinical biomarkers for hepatocellular carcinomas. J Clin Med. 2015;4:1631–50. [PMC free article] [PubMed] [Google Scholar]
Ba MC, Long H, Tang YQ, Cui SZ. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma:a review. Int J Clin Exp Pathol. 2012;5:874–81. [PMC free article] [PubMed] [Google Scholar]
Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. [PubMed] [Google Scholar]
Biselli-Chicote PM, Oliveira AR, Pavarino EC, GoloniBertollo EM. VEGF gene alternative splicing:pro and antiangiogenic isoforms in cancer. J Cancer Res Clin Oncol. 2012;138:363–70. [PubMed] [Google Scholar]
Bruix J, Sherman M. Management of hepatocellular carcinoma:an update. Hepatology. 2011;53:1020–2. [PMC free article] [PubMed] [Google Scholar]
Buitrago-Molina LE, Vogel A. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets. 2012;12:1045–61. [PubMed] [Google Scholar]
Burchard J, Zhang C, Liu AM, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6:1–12. [PMC free article] [PubMed] [Google Scholar]
Carethers JM, Braun J, Sands BE. Genetics, genetic testing, and biomarkers of digestive diseases. Gastroenterology. 2015;149:1131–3. [PMC free article] [PubMed] [Google Scholar]
Cervello M, McCubrey JA, Cusimano A, et al. Targeted therapy for hepatocellular carcinoma:novel agents on the horizon. Oncotarget. 2012;3:236–60. [PMC free article] [PubMed] [Google Scholar]
Chen LP, Li C, Wen TF, et al. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? Pak J Med Sci. 2015;31:763–9. [PMC free article] [PubMed] [Google Scholar]
Cheng J, Wang W, Sun C, et al. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol. 2014;48:806–14. [PubMed] [Google Scholar]
Chimparlee N, Chuaypen N, Khlaiphuengsin A, et al. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16:7211–7. [PubMed] [Google Scholar]
Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma:an international consensus conference report. Lancet Oncol. 2012;13:e11–22. [PMC free article] [PubMed] [Google Scholar]
Dargel C, Stemberg B, Hasreiter J, et al. T Cells engineered to express a T-cell receptor specific for Glypican-3 to recognize and kill Hepatoma cells in vitro and in mice. Gastroenterol. 2015;149:1042–52. [PubMed] [Google Scholar]
De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepato. 2012;56:75–87. [Google Scholar]
Dong Q, Zhu X, Dai C, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016;7:12997–13012. [PMC free article] [PubMed] [Google Scholar]
Eagon P. Alcoholic liver injury:Influence of gender and hormones. World J Gastroenterol. 2010;16:1377–84. [PMC free article] [PubMed] [Google Scholar]
Elmashad N, Ibrahim WS, Mayah WW, et al. Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16:613–9. [PubMed] [Google Scholar]
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73. [PMC free article] [PubMed] [Google Scholar]
European Association for the Study of the liver. European organization for research and treatment of cancer. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatol. 2012;56:908–
Antibodies:a new therapeutic target for liver cancer. FEBS Lett. 2014;588:377–82. [PMC free article] [PubMed] [Google Scholar]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86. [PubMed] [Google Scholar]
Fish JE, Srivastava D. MicroRNAs:opening a new vein in angiogenesis research. Sci Signal. 2009;2:1–7. [PMC free article] [PubMed] [Google Scholar]
Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev ClinOncol. 2014;11:525–35. [PubMed] [Google Scholar]29. Ge YY, Shi Q, Zheng ZY, et al. MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by
inhibiting the expression of mTOR and IGF-1R. Oncotarget. 2014;5:6218–28. [PMC free article] [PubMed] [Google Scholar]
Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma:epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras. 2013;59:51424. [PubMed] [Google Scholar].